Athersys Raises $23 Million in Public Offering

Athersys, a Cleveland regenerative medicine company, raises $23 million in a public offering. Funds will be used for working capital and general corporate purposes, including funding a Phase 3 clinical trial for ischemic stroke.

Read More  >